Bevolkingsonderzoek

What Bevolkingsonderzoek does

Bevolkingsonderzoek Nederland is a Netherlands-based organization that carries out three government-commissioned population screening programs for cancer: breast cancer (mammography for women aged 50-75, invitations every 2-3 years), cervical cancer (HPV testing via GP smear or at-home self-test for women aged 30-60, invitations every 5-10 years), and colorectal cancer (fecal immunochemical stool test for adults aged 55-75, every 2 years). It operates a national infrastructure of mobile mammography buses that rotate through Dutch communities, a network of four collaborating laboratories for stool sample analysis, and partner GP practices and hospitals for follow-up diagnostics including colonoscopy. A DigiD-authenticated online portal, Mijn Bevolkingsonderzoek, allows participants to manage appointments and access results.

Name

Bevolkingsonderzoek

Legal name

Bevolkingsonderzoek Nederland

Website

https://bevolkingsonderzoeknederland.nl

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Bevolkingsonderzoek Nederland is a Dutch government-commissioned organization that operates free nationwide population screening programs for breast, cervical, and colorectal cancer, serving age-defined cohorts of Dutch residents via mobile mammography units, mailed home tests, and GP-based sampling.

Ownership category

akta.pro rank

Product category

Population cancer screening services

NAICS

Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215), Testing Laboratories and Services (54138)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Chronic Disease & NCD Program Evaluation (e.g., diabetes/CVD/cancer) (HLAJANAG)

Keywords

• Cancer population screening
• Breast cancer screening
• Cervical cancer screening
• Colorectal cancer screening
• Government health screening

Headquarters

HQ city

Utrecht

HQ country

Netherlands

HQ region

Europe

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Government-Funded Screening Services: Population screening programs are fully funded by the Dutch government through RIVM (National Institute for Public Health and the Environment). Participation is free for all invited citizens. The organization operates under government mandate to provide cancer screening services.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Bevolkingsonderzoek Nederland operates the Dutch government's three population screening programs for cancer: breast cancer screening via mammography for women aged 50-75, cervical cancer screening via HPV testing (smear at GP or home self-test) for women aged 30-60, and colorectal cancer screening via stool testing for adults aged 55-75. Services are delivered through mobile screening units, mailed home-test kits, GP referrals, and a unified online portal, and are funded by RIVM so participation is free for invited citizens.

Product overview

Bevolkingsonderzoek Nederland operates three distinct population screening programs for cancer detection commissioned by RIVM: breast cancer screening (mammography for women 50-75), cervical cancer screening (HPV testing via smear test or self-test for women 30-60), and colorectal cancer screening (stool tests for people 55-75). Participation is free and voluntary. The three screenings are accessed through a unified portal (Mijn Bevolkingsonderzoek) and result delivery system, though each has its own dedicated website section and specific testing methodology.

Differentiator

Problem solved

Functional benefit

Products and services

• Bevolkingsonderzoek Borstkanker (Breast Cancer Screening) Population screening program for breast cancer using mammography (X-rays of the breasts) for women aged 50-75. Women are invited every 2-3 years when a mobile screening center is in their area, with mammograms independently reviewed by two radiologists and a third providing tiebreaker review when needed.
• Bevolkingsonderzoek Baarmoederhalskanker (Cervical Cancer Screening) Population screening program for cervical cancer through HPV testing for women aged 30-60. Women can provide a smear via their GP or use a mailed HPV self-test collected at home and returned by post; invitations are issued at ages 30, 35, 40, 50, and 60, with additional invitations for non-participants.
• Bevolkingsonderzoek Darmkanker (Colorectal Cancer Screening) Population screening program for colorectal cancer using fecal immunochemical testing (FIT) stool tests for adults aged 55-75. Participants receive test kits in the mail every two years, mail samples back to one of four collaborating laboratories, and are referred for diagnostic colonoscopy at a hospital center when blood is detected.
• Mijn Bevolkingsonderzoek (Client Portal) Online client portal (Mijn Bevolkingsonderzoek) for invited Dutch residents to schedule, change, or cancel appointments, request new invitations for breast, cervical, and colorectal screening, and access their screening results via DigiD authentication.

Quantifiable outcome

• Phase 3 and 4 colorectal cancer cases have significantly decreased since screening program started in 2014
• +2 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• RIVM (Rijksinstituut voor Volksgezondheid en Milieu)coreStrategic or Co-development PartnerBevolkingsonderzoek Nederland operates population screening programs commissioned by RIVM (National Institute for Public Health and the Environment). RIVM determines data sets for each screening program and sets quality standards. The organization follows the Legal Framework for Data Exchange in Cancer Screening established by RIVM.

Scale indicators8 records

Recent moves8 records

Expansion highlights4 records

Broad incumbents

• Sysmex: Provides the OC-Sensor and other fecal immunochemical testing (FIT) analyzers widely used in population colorectal cancer screening programmes. Direct technology counterpart to the lab infrastructure supporting Bevolkingsonderzoek's CRC screening.
• Qiagen: Supplier of HPV molecular diagnostic tests (digene HC2, QIAscreen) used in cervical cancer screening programmes worldwide. Comparable as a key enabling technology vendor for Bevolkingsonderzoek's cervical cancer screening operations.
• Hologic: Leading supplier of mammography systems (3Dimensions) and HPV molecular diagnostics (Panther) used in population breast and cervical screening programmes globally. Comparable as the dominant technology vendor enabling breast and cervical screening at Bevolkingsonderzoek's scale.

Emerging players

• Exact Sciences: Makers of Cologuard, the leading at-home stool-DNA colorectal cancer screening test competing with traditional FIT-based population screening programmes like Bevolkingsonderzoek's CRC offering. Represents the most direct commercial overlap in the CRC screening category.
• Guardant Health: Developer of blood-based multi-cancer screening tests (Shield for CRC, Reveal for MCED). Represents the next-generation screening modality that may compete with or complement Bevolkingsonderzoek's stool-based CRC and mammography programmes.

Regional players

• Cancer Council Australia: Coordinates Australia's National Bowel Cancer Screening Program and supports national cervical screening. Operates population-based screening at scale but in a different geography with state-level delivery partners.
• Finnish Cancer Registry: Operates Finland's national cancer screening registries and supports the Finnish Mass Screening Registry covering breast and cervical cancer. Closely mirrors Bevolkingsonderzoek's role as national screening data steward but serves a separate Nordic jurisdiction.
• Norwegian Directorate of Health (cervical/breast screening): Administers Norway's population-based cervical (Cervixscreen) and breast cancer screening programmes. Highly comparable structurally, operating under government mandate with similar target age cohorts and lab-based testing, but serving a separate national market.

Direct peers

• NHS England Cancer Screening Programmes: Operates the UK's national breast, cervical, and bowel cancer screening programmes on a similar government-commissioned model. Directly comparable as a population-based cancer screening operator serving an entire country's eligible cohorts, with analogous infrastructure (mobile units, lab networks, invitation systems).
• Public Health Scotland (Detect Cancer Early): Runs Scottish national cancer screening programmes including breast, cervical, and bowel screening with government commissioning and population-based invitations. Closely aligned with Bevolkingsonderzoek Nederland in operating model, target cohorts, and public health mandate.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights1 record

Customer concentration

• Xx.com/bvo_nederland
• Facebookfacebook.com/bevolkingsonderzoeknederland
• LinkedInlinkedin.com/company/bevolkingsonderzoeknederland

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bevolkingsonderzoek